Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest update is out from Shanghai Junshi Biosciences Co., Ltd. Class H ( (HK:1877) ).
Shanghai Junshi Biosciences has received approval from China’s National Medical Products Administration for a supplemental new drug application expanding toripalimab’s use, in combination with RemeGen’s antibody-drug conjugate disitamab vedotin, as a first-line treatment for HER2-expressing locally advanced or metastatic urothelial carcinoma. This marks the 13th approved indication for toripalimab in mainland China and strengthens its position as a leading domestic PD-1 therapy with broad reimbursement and international reach.
The new indication is supported by phase III trial data showing toripalimab plus disitamab vedotin significantly improved progression-free survival, overall survival, response rates and safety versus standard chemotherapy in treatment-naive HER2-expressing urothelial carcinoma patients. The approval addresses a major unmet need in a cancer with rising incidence and mortality in China, enhances Junshi’s competitive standing in immuno-oncology, and may drive wider clinical adoption and market uptake of toripalimab-based combinations in both domestic and global markets.
The most recent analyst rating on (HK:1877) stock is a Hold with a HK$34.70 price target. To see the full list of analyst forecasts on Shanghai Junshi Biosciences Co., Ltd. Class H stock, see the HK:1877 Stock Forecast page.
More about Shanghai Junshi Biosciences Co., Ltd. Class H
Shanghai Junshi Biosciences Co., Ltd. is a China-based biopharmaceutical company focused on developing and commercializing innovative oncology therapies, particularly immuno-oncology drugs such as the PD-1 monoclonal antibody toripalimab. The company has advanced a broad global clinical program, with toripalimab approved for multiple tumor types in over 40 countries and extensively incorporated into China’s National Reimbursement Drug List, underscoring its growing presence in both domestic and international cancer treatment markets.
Average Trading Volume: 3,920,931
Technical Sentiment Signal: Sell
Current Market Cap: HK$39.9B
Learn more about 1877 stock on TipRanks’ Stock Analysis page.